论文部分内容阅读
据Meyer AS 2013年8月6日[Sci Signal,2013,6(287):ra66-ra66.]报道,美国麻省理工学院一项新的研究揭示了这个耐药现象出现的一种机制,是因为一种蛋白质AXL帮助癌细胞规避ErbB抑制剂的影响,让癌细胞不受控制地生长。虽然癌症治疗药物如ErbB抑制剂在治疗肺癌、乳腺癌、结肠癌和其他类型癌症患者中已经表现出了极大的成功。然而,仍有其他许多患者不回应ErbB抑制剂,即患者出现了药物耐药,即使是那些肿瘤复发患者也会出现耐药现象。麻省理工学院研究结果表明,联合靶向AXL和ErbB受体的药物,可以是一种更好的方式来对付肿瘤。
According to a report by Meyer AS on August 6, 2013 [Sci Signal, 2013,6 (287): ra66-ra66.], A new study at the Massachusetts Institute of Technology reveals a mechanism by which the drug resistance phenomenon occurs Because one protein, AXL, helps cancer cells bypass the effects of ErbB inhibitors, let cancer cells grow uncontrollably. Although cancer therapy drugs such as ErbB inhibitors have shown great success in the treatment of lung cancer, breast cancer, colon cancer and other types of cancer patients. However, many other patients do not respond to ErbB inhibitors, ie patients develop drug resistance and even those with tumor recurrences develop resistance. Massachusetts Institute of Technology results show that the joint targeting of drugs AXL and ErbB receptors can be a better way to deal with tumors.